You Han Bae,
Distinguished Professor, Department of Pharmaceutics and Pharmaceutical Chemistry,
University of Utah
Dr. You Han Bae is Distinguished Professor in Pharmaceutics at the University of Utah. His expertise includes responsive polymers and their biomedical applications and novel delivery systems for cells, proteins, genes, and small molecules. In these fields, he has published more than 290 research articles/book chapters/patents and been recognized as one of Highly Cited Researchers each year for 2014-2018 (by Thomson Reuters and Clarivate Analyatics) in the field of pharmacology. He is an elected fellow of AIBME, AAPS, and CRS. He is currently interested in oral nanoparticle absorption and combinatory gene therapy of metabolic diseases. He is serving on Journal of Controlled Release as an Associate Editor in America and the editor of Concept Paper of the same journal.
New Oral Absorption Pathway of Nanoparticle
Tuesday, 10 September 2019 at 10:00
Add to Calendar ▼2019-09-10 10:00:002019-09-10 11:00:00Europe/LondonNew Oral Absorption Pathway of NanoparticleCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com
All nanomedicine assumes injection for administration. Biologics show extremely poor oral bioavailability due primarily to limited solubility, low permeability and digestive enzymes. Clinical trials of various small-sized peptides (not larger than insulin) with permeation enhancers and enzyme inhibitors have documented only limited oral bioavailability. If protective nanoparticles loaded with such active ingredients were absorbed from the gastrointestinal tract, it would overcome most of issues relevant to poor bioavailability. Various approaches for nanoparticle oral delivery, based on receptor-mediated endocytosis and M-cell uptake, have been explored, the uptake rates have, however, been limited and their clinical translation yet remains to be proven.
We are exploring paradigm-shifting approaches for intestinal absorption of intact nanoparticles by combining fat digestion processes and enterohepatic recycling of bile acids.
Nanoparticles of which surfaces are modified with bile acids are transported, after oral administration, to the ileum, bind apical sodium-dependent bile acid transporter (ASBT), and are absorbed by unknown endocytic pathways. The nanoparticles then seem to share the transport pathway of chylomicron. This presentation will demonstrate solid evidences supporting a new nanoparticle uptake pathway, report a platform nanotechnology for oral drug delivery, and summarize high oral bioavailability of selected small molecules, peptides/proteins and nucleic acids at a reasonable dose range to meet corresponding therapeutic windows in rodent models.
Add to Calendar ▼2019-09-09 00:00:002019-09-10 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-09-10 10:00:002019-09-10 11:00:00Europe/LondonNew Oral Absorption Pathway of NanoparticleCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com
